International Journal of Medical and Dental Sciences

Open Access Open Access  Restricted Access Subscription Access

New Ray of Hope for Psychosis in Parkinsons:Pimavanserin


Affiliations
1 Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
 

Parkinson's disease is often associated with hallucinations and psychosis. Till now typical and atypical antipsychotics (Clozapine&Quetiapine) are being used to manage these symptoms. Recently US FDA has approved a new drug Pimavanserin for the treatment of hallucination and delusion associated with parkinson's disease psychosis in a dose of 34 mg.

Keywords

Hallucinations, Delusions, Psychosis, Parkinsonism, Pimavanserin.
User
Notifications
Font Size


  • Olanow CW, Schapira AHV, Obeso JA. Parkinsons disease and other movement disorders. In: Kasper, Fauci, Hauser, Longo Jameson, Loscalzo, editors. Harrisons principles of internal medicine 19th ed. New York: Mc Graw Hill Education; 2015.p.2617.

  • Highlights of prescribing information. Available at: www.access data.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf. Accessed on 15.05.2016.

  • Cummings J, Isaacson S, Mills R, Williams H, Chi-burris K, Corbett A, et al. Pimavanserin for patients with parkinson’s disease psychosis: a randomised, placebo- controlled phase 3 trial. The Lancet. http://dx.doi.org/10.1016/S0140-6736(13)62157-1.


Abstract Views: 184

PDF Views: 135




  • New Ray of Hope for Psychosis in Parkinsons:Pimavanserin

Abstract Views: 184  |  PDF Views: 135

Authors

N. Grewal
Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
R. Kumar
Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
B. Jassal
Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, India

Abstract


Parkinson's disease is often associated with hallucinations and psychosis. Till now typical and atypical antipsychotics (Clozapine&Quetiapine) are being used to manage these symptoms. Recently US FDA has approved a new drug Pimavanserin for the treatment of hallucination and delusion associated with parkinson's disease psychosis in a dose of 34 mg.

Keywords


Hallucinations, Delusions, Psychosis, Parkinsonism, Pimavanserin.

References





DOI: https://doi.org/10.18311/ijmds%2F2016%2F100633